OPKO Health, Inc. splits its revenue into 3 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Product at $41.8 million, 64% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
654
|
65
|
164
|
124
|
148
|
56
|
157
|
150
|
184
|
| Services |
—
|
—
|
75
-26.3%
share 45.6%
|
72
-29.8%
share 58.1%
|
71
-31.1%
share 47.9%
|
95
share 168.8%
|
101
share 64.5%
|
103
share 68.6%
|
103
share 56.1%
|
| Product |
—
|
42
+11.0%
share 63.9%
|
43
+5.4%
share 26.3%
|
38
+9.2%
share 30.6%
|
44
+16.6%
share 29.4%
|
38
share 66.8%
|
41
share 26.0%
|
35
share 23.2%
|
37
share 20.4%
|
| License And Service |
—
|
24
+25.9%
share 36.1%
|
46
+208.0%
share 28.2%
|
14
+13.9%
share 11.2%
|
34
-21.8%
share 22.7%
|
19
share 33.2%
|
15
share 9.5%
|
12
share 8.2%
|
43
share 23.5%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OPK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami, FL
- SEC filer status
- Accelerated filer
- SEC CIK
- 944809
- Former names
- EXEGENICS INC (until Jun 13, 2007); eXegenics Inc (until Jun 13, 2007); CYTOCLONAL PHARMACEUTICS INC /DE (until Jun 4, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.